| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 29.73 | 39.2% | 22.9% |
| Total Income | 29.73 | 39.2% | 22.9% |
| Expenditure | 82.14 | 3.0% | 4.8% |
| PBT | — | ||
| Net Profit | -61.94 | 12.6% | 3.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.20 | 13.0% | 2.6% |
REGENXBIO Reports Q3 2025 Financial Results and Operational Highlights
04 May 2026 · 4 May, 7:48 am
Summary
REGENXBIO reported its third quarter 2025 financial results, with revenues increasing to $29.7 million compared to $24.2 million in the same period of the previous year. The company's cash position remains strong at $302.0 million. Net loss for the quarter was $61.9 million, slightly higher than the $59.6 million loss in Q3 2024. The company anticipates its cash balance will fund operations into early 2027. Several key clinical milestones are expected in the coming quarters, including topline data for RGX-202 and sura-vec.
Key Highlights
- 1
REGENXBIO reported revenues of $29.7 million for the three months ended September 30, 2025, compared to $24.2 million for the three months ended September 30, 2024.
- 2
The company's cash, cash equivalents, and marketable securities totaled $302.0 million as of September 30, 2025, compared to $244.9 million as of December 31, 2024.
- 3
Research and development expenses were $56.1 million for the three months ended September 30, 2025, compared to $54.4 million for the three months ended September 30, 2024.
- 4
Net loss was $61.9 million, or $1.20 basic and diluted net loss per share, for the three months ended September 30, 2025, compared to a net loss of $59.6 million for the same period in 2024.
- 5
Topline results for the RGX-202 program for Duchenne muscular dystrophy are expected in early Q2 2026, with a BLA submission anticipated in mid-2026.
- 6
The PDUFA date for clemidsogene lanparvovec (RGX-121) is February 8, 2026.
- 7
Topline data for surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD is expected in Q4 2026.
Management Comments
Curran M. Simpson
“The positive data and significant clinical milestones achieved across each of our late-stage programs underscore the meaningful progress we’re making towards delivering potentially transformative gene therapies. Our strong momentum is driven by our differentiated, in-house end-to-end capabilities, including commercial-ready manufacturing with capacity to seize blockbuster opportunities, and a deep commitment to improve the lives of patients with Duchenne, Hunter syndrome, wet AMD and diabetic retinopathy. With the rapid advancement of our programs and leading technology platform, we are well-positioned to become a commercial company early next year.”
Informational and educational content only. Not investment advice.